How to read a tag. Only
verified counts toward a score — it means a typed connector
resolved this against a primary US federal record.
unconfirmed means the Verifier checked and could not confirm,
which very often means the source could not be queried at all rather than that
the claim is doubtful. refuted means a primary source
contradicts it. unverified means nothing has checked it yet.
Neonatal phototherapy units are Class II (FDA device class II) under 21 CFR (Title 21 of the Code of Federal Regulations) 880.5700, product code LBI, and reach market via 510(k) (premarket notification) premarket notification
jurisdiction: US — confidence: verified — source: openFDA device/classification product_code=LBI ("Device class 2: Unit, Neonatal Phototherapy, regulation 880.5700, review panel HO") + eCFR versioner title-21, issue 2026-08-19, section=880.5700 ("(b) Classification. Class II (performance standards)"). **Checked…the full check against the stated intended_use:** — "for use in the home under prescription to deliver phototherapy to newborns of at least 35 weeks gestational age with uncomplicated indirect hyperbilirubinemia ... as an alternative to inpatient readmission for phototherapy." The CFR identification text is a match for that use as written: "a device used to treat or prevent hyperbilirubinemia (elevated serum bilirubin level). The device consists of one or more lamps that emit a specific spectral band of light, under which an infant is placed for therapy." That match is treatment-delivery-only; if the indication is ever widened to include any bilirubin measurement claim, this verification lapses and the carried second device_class route applies. The 510(k) pathway leg is corroborated by claim-typed lookups of four devices cleared under LBI (see next claim). Two things this check does NOT establish: the eCFR text contains no exemption language and no enumerated special controls, so the Scorer's "special-controls scrutiny on photometric accuracy" rationale is not supported by the section text (openFDA classification records carry no exemption/special-controls field either).
Predicate availability is not the constraint: multiple devices have been cleared under LBI, including at least one wearable form factor (SnugLit Wearable Phototherapy System, K251308 (an FDA 510(k) clearance number), FDA (US Food and Drug Administration) decision date 2026-01-15)
jurisdiction: US — confidence: verified — source: openFDA device/510k k_number=K251308 ("SnugLit(TM) Wearable Phototherapy System (SNGL-01-US) / Thera B Medical Products"); multiplicity corroborated by four independent claim-typed 510(k) lookups: K251308 (SnugLit, wearable), K243372 (BiliWrap / Gerium Medical),…the full check K103589 (neoBLUE blanket LED / Natus), K120168 (Lullaby LED / Wipro GE Healthcare). Date — re-checked cold 2026-08-25, and now stated in the claim text above rather than only annotated down here. The primary record gives decision date 2026-01-15: 510k "SnugLit" --jurisdiction US returned verified, source_ref openFDA device/510k k_number=K251308, detail "Cleared 510(k): SnugLit(TM) Wearable Phototherapy System (SNGL-01-US) / Thera B Medical Products decided 2026-01-15". The proposition "K251308 was cleared in 2025" is contradicted by the primary record read as a statement about the decision date — no 2025 decision date exists on this record. That is not a refutation of this claim line, and the tag is deliberately not being downgraded: what this line asserts is predicate availability plus the existence of a cleared wearable analog, and the same record verifies both. The claim was imprecise, not wrong — but the imprecision has been removed from the claim text, not left standing with a footnote. The benign explanation is itself unverified: the reading that "K25xxxx" encodes the submission year is plausible, but the connector returns no date_received field, so nothing in this repo establishes from a primary source that K251308 was submitted in 2025. Anyone restating "2025" must say which date they mean and cite something that carries it. predicate_or_analog: in the frontmatter still reads "cleared 2025" and is flagged, not edited — frontmatter is Generator territory (this is the second pass to flag it). Indications-for-Use read directly (the load-bearing half), FDA 510(k) summary K251308 (https://www.accessdata.fda.gov/cdrh_docs/pdf25/K251308.pdf), verbatim: "The SnugLit(TM) Wearable Phototherapy System is intended for use in the treatment of infant hyperbilirubinemia, commonly known as neonatal jaundice. The device can be used in a hospital or at home, by a licensed medical practitioner or by a caregiver under the supervision of a licensed medical practitioner. The device has been designed for use with infants of weights between 1.5 - 5.5 kg (approximately 3.5 -12 lbs) and lengths between 40.5 - 57.5 cm (approximately 16 - 23 inches)." An --expect-indication "home" check returned verified. Read this before treating it as a friendly predicate: the cleared indication is broader than this candidate's — it is scoped by weight and length, carries no gestational-age floor and no bilirubin-band ceiling, and explicitly permits caregiver-administered home use. Whether that supports substantial equivalence for the narrower proposed indication is an FDA judgement, not a connector output. It also means the closest analog already occupies the home-wearable indication without the 35-week/in-band scoping this file treats as its de-risking lever. IFU (instructions for use) re-read cold on 2026-08-25 — clearance-summary K251308 --jurisdiction US returned verified against the same source_ref and returned the identical verbatim text, so the quotation above is confirmed twice from the summary PDF, not carried forward from a previous pass. On the specific predicate_or_analog: position that SnugLit "is itself a wearable form factor and is the closest analog, not a differentiator": the IFU supports that position, and slightly understates it. The cleared indication covers hospital and home use, caregiver-administered under practitioner supervision, across 1.5-5.5 kg and 40.5-57.5 cm — which contains essentially the whole 35+ week population this candidate targets and more, with no gestational-age floor and no bilirubin-band ceiling to carve out a distinct lane. Nothing in the IFU claims dosimetry, an irradiance record, or an adherence record, so the specific differentiator this candidate proposes is not visibly occupied by the cleared indication — but "closest analog, not a differentiator" is the correct reading of the form factor and the setting, and it is a verified-record reading rather than an inference. Second wearable/wrap entrant, IFU also read (FDA 510(k) summary K243372): BiliWrap is "intended for use to treat infants who have been diagnosed with hyperbilirubinemia ... can be used in a hospital or at home ... in infants up to the age of 3 months, weighing less than 10 kg."
HCPCS (Healthcare Common Procedure Coding System) E0202 (a HCPCS code for durable medical equipment) exists and is descriptor-defined as "Phototherapy (bilirubin) light with photometer"
jurisdiction: US — confidence: verified — note: tag moved unconfirmed → verified on the 2026-09-29 (second pass) re-check after data/hcpcs_level_ii.csv was cached — a now-answers (our reach), not a change in the world. Code existence and descriptor text only: that the code exists says nothing about payment (claim 5verified)…the full check or coverage (see claim 5verified's coverage leg) — source: hcpcs E0202 --jurisdiction US → verified, local cache of CMS (Centers for Medicare & Medicaid Services) HCPCS Level II file, code=E0202 (October 2026 Alpha-Numeric release, retrieved 2026-09-29): "HCPCS E0202: Phototherapy (bilirubin) light with photometer" — action code N, added 1985-01-01, no termination date; hcpcs E0202 --expect "Phototherapy (bilirubin) light with photometer" --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0202: "HCPCS E0202: Phototherapy (bilirubin) light with photometer". History (earlier pass, superseded): hcpcs E0202 --jurisdiction US returned: "No local cache at data/hcpcs_level_ii.csv — HCPCS Level II code E0202 cannot be checked until it exists. See data/README.md for the exact CMS source and expected columns. Do not substitute a web search for this file." Nothing was searched. This is a missing-input result, not a negative finding: it is not evidence that E0202 fails to exist. Resolving it requires a human to place the CMS HCPCS Level II file in data/.
The E0202 descriptor requires both the light and a photometer, such that a unit supplied without a photometer does not meet the descriptor
jurisdiction: US — confidence: verified — note: tag moved unconfirmed → verified on the 2026-09-29 (second pass) re-check; now-answers, not a change in the world. Verified as a statement about the descriptor text — the CMS long descriptor is "light with photometer", and it is the only phototherapy-light code in…the full check the Level II file (the other phototherapy entries are S0812 (a HCPCS temporary national code), keratectomy, and S9098, a per-diem home phototherapy service code). It does not verify the file's stronger premise that the photometer is "a condition of billing the code at all" as a payment rule: whether suppliers are held to it is DME MAC (durable medical equipment Medicare administrative contractor) / PDAC (Pricing, Data Analysis and Coding contractor) coding-verification and payer-edit territory, not in the HCPCS file, and the payers that matter here (Medicaid, commercial) apply their own edits. Both limits recorded in the history below still stand — source: hcpcs E0202 --expect "Phototherapy (bilirubin) light with photometer" --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0202: "HCPCS E0202: Phototherapy (bilirubin) light with photometer"; hcpcs E0202 --expect "photometer" --jurisdiction US → verified, same source_ref. History (earlier pass, superseded): hcpcs E0202 --expect "Phototherapy (bilirubin) light with photometer" --jurisdiction US returned the same missing-cache result: "No local cache at data/hcpcs_level_ii.csv — HCPCS Level II code E0202 cannot be checked until it exists." Recorded precisely because this is the most load-bearing line in the file: the onboard photometer is justified in ## Indication-scope note as "a condition of billing the code at all," and the Moat and Reimbursement factor rationales both lean on it. The check did not run against any source — no lookup occurred, no descriptor text was retrieved, and the pre-existing coding-aggregator basis remains a secondary source this pipeline does not accept. Two further limits even once the cache exists: (a) the CMS descriptor is a short/long descriptor string, and whether "with photometer" is binding for payment (vs. merely descriptive) is a payment-policy and DME (durable medical equipment)-MAC (Medicare administrative contractor)-supplier-manual question the HCPCS file cannot settle; (b) the payers that matter here are Medicaid and commercial, whose descriptors and edits are not in this file at all. Treat the photometer-as-billing-condition premise as unverified in both senses until a human attaches the CMS file and a payer policy.
E0202 carries a published DMEPOS (durable medical equipment, prosthetics, orthotics and supplies) fee-schedule allowable
jurisdiction: US — confidence: verified — note: tag moved unconfirmed → verified on the 2026-09-29 re-check; this is a now-answers (the DMEPOS fee schedule was cached into data/), not a change in the world. What it verifies is narrow: CMS publishes a Medicare DMEPOS allowable for E0202, on **one pricing line only —…the full check RR, capped rental, billed per rental month** — with no NU/UE purchase line. It is Medicare's allowed amount; newborns are not Medicare beneficiaries (claim 6unconfirmed), so it says nothing about what Medicaid or commercial plans pay, and a fee existing is not coverage — the coverage leg is still missing its cache, and the code-descriptor leg (claims 3-4) is still missing data/hcpcs_level_ii.csv. Two of the three reimbursement questions remain open; this is not a demonstrated pathway — source: payment E0202 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0202, modifier=RR, schedule=DMEPOS, release=July 2026: "E0202 — RR (rental), category CR — capped rental items: non-rural $75.86 (AZ) to $89.25 (AL) across 49 contiguous states/DC. ... A fee schedule amount is Medicare's allowed amount, not the payment ... Capped rental (CR): rented monthly, and title passes to the beneficiary after 13 continuous rental months (42 CFR 414.229)."; payment E0202 --modifier NU --jurisdiction US → unconfirmed: "E0202 is on the DMEPOS fee schedule (July 2026) but has no 'NU' line. Its lines are: RR."; coverage E0202 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv" (file still absent from data/). History (earlier pass, superseded): payment E0202 --jurisdiction US → unconfirmed: payment E0202 --jurisdiction US returned: "No local cache at data/hcpcs_payment_rates.csv — payment rate for E0202 cannot be checked until it exists. See data/README.md for the exact CMS source and expected columns." The amount remains unknown and was not guessed here either. Note the three-part reimbursement test: existence, payment, and coverage are separate questions and none of the three resolved — coverage E0202 --jurisdiction US likewise returned "No local cache at data/medicare_coverage_policies.csv." A code with no confirmed descriptor, no confirmed rate, and no confirmed coverage policy is not a demonstrated pathway. Re-check 2026-09-29 (second pass): the coverage leg now runs: coverage E0202 --jurisdiction US → refuted, local cache of CMS Medicare Coverage Database (no policy names this code), code=E0202: "No NCD (national coverage determination) or LCD (local coverage determination) in the cached coverage file names E0202 ... This is a real reimbursement risk signal, but it is NOT the same as a denial" — read with two limits: the cached file is the MCD Billing & Coding Articles export only (current_article.zip, 1,970 rows), so LCDs and NCDs proper were not searched despite the detail's wording; and coverage tests whether a policy names the code, never whether it is covered. claim 5verified's tag is unaffected (it asserts a fee-schedule allowable, not coverage); code existence is now verified too (claims 3-4). So the three-part test reads: code exists — verified; Medicare allowable — verified (monthly RR only); Medicare coverage policy naming the code — none in the cached articles. Still not a demonstrated pathway, and all three legs are Medicare's.
Structural reimbursement note, not a hopeful one: newborns are not Medicare beneficiaries, so the payers that matter here are Medicaid (roughly 40%+ of US births) and commercial plans, and the Medicare-anchored connectors in this repo will therefore reach only part of the question
jurisdiction: US — confidence: unconfirmed — source: no connector answers this; it is a reasoning claim about scope, not a lookup, and no connector in this repo queries Medicaid or commercial payer policy. The Verifier can confirm only the operational half from its own run log: payment E0202 and coverage E0202…the full check both returned missing-cache unconfirmed, so this pass produced no Medicare-shaped answer either — the Medicaid/commercial gap is therefore additive to, not instead of, an unresolved Medicare picture. The 40%+ Medicaid birth-share figure is itself uncited (NCHS/CMS would be primary) and is not verified here. Factor 2 is unsettled on every available axis. Re-check 2026-09-29: the Medicare-shaped half now partly answers — payment E0202 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0202, modifier=RR, schedule=DMEPOS, release=July 2026: "E0202 — RR (rental), category CR — capped rental items: non-rural $75.86 (AZ) to $89.25 (AL) across 49 contiguous states/DC. ... A fee schedule amount is Medicare's allowed amount, not the payment ... Capped rental (CR): rented monthly, and title passes to the beneficiary after 13 continuous rental months (42 CFR 414.229)." — so a Medicare DMEPOS allowable exists (monthly RR line only), while coverage E0202 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv" (file still absent from data/). Tag unchanged: this claim is about payer scope, the Medicare fee does not speak to Medicaid or commercial payment, and the Medicaid birth-share figure is still uncited. Re-check 2026-09-29 (second pass): the coverage leg now runs: coverage E0202 --jurisdiction US → refuted, local cache of CMS Medicare Coverage Database (no policy names this code), code=E0202: "No NCD or LCD in the cached coverage file names E0202 ... This is a real reimbursement risk signal, but it is NOT the same as a denial" — read with two limits: the cached file is the MCD Billing & Coding Articles export only (current_article.zip, 1,970 rows), so LCDs and NCDs proper were not searched despite the detail's wording; and coverage tests whether a policy names the code, never whether it is covered. Tag unchanged — still a scope claim about which payers matter.
TAM (total addressable market) component 1 — annual US births are approximately 3.6 million
jurisdiction: US — confidence: unconfirmed — source: no primary source available. market returned unverifiable: "Market-size claim has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand." Note for whoever picks this…the full check up: unlike most TAM inputs this one does have a free authoritative source (NCHS/CDC WONDER natality final birth data) — it is simply outside this repo's connector set, so it needs a human attachment rather than a licensed report.
TAM component 2 — the share of newborns at or above 35 weeks who receive phototherapy for hyperbilirubinemia is on the order of 8-12%
jurisdiction: US — confidence: unconfirmed — source: no primary source available. market returned unverifiable (same detail as above). Remains, as the file itself states, the largest lever and the least defensible number; a published birth-cohort study would be the primary source and is a human attachment, not a…the full check connector call.
TAM component 3 — the share of phototherapy-treated newborns clinically eligible for home rather than inpatient treatment (uncomplicated, in-band, reliable follow-up available) is assumed by the Generator at 25-40%
jurisdiction: US — confidence: unconfirmed — source: no primary source available. market returned unverifiable (same detail).
TAM component 4 — net revenue per home phototherapy episode to the supplier is on the order of the E0202 rental allowable for a 2-4 day episode plus setup
jurisdiction: US — confidence: unconfirmed — source: no primary source available. market returned unverifiable; and its stated dependency, the E0202 allowable, is itself unconfirmed for missing cache. Doubly unresolved. Re-check 2026-09-29: the stated dependency now partly resolves and cuts against the…the full check claim's shape: payment E0202 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0202, modifier=RR, schedule=DMEPOS, release=July 2026: "E0202 — RR (rental), category CR — capped rental items: non-rural $75.86 (AZ) to $89.25 (AL) across 49 contiguous states/DC. ... A fee schedule amount is Medicare's allowed amount, not the payment ... Capped rental (CR): rented monthly, and title passes to the beneficiary after 13 continuous rental months (42 CFR 414.229).". The only published Medicare E0202 allowable is a monthly capped-rental fee, so there is no Medicare per-episode allowable for a 2-4 day episode to multiply, and in any case it is Medicare's rate for a population with no Medicare exposure. Tag unchanged — market remains unverifiable.
The 2022 AAP clinical practice guideline on hyperbilirubinemia in newborns of 35+ weeks raised phototherapy initiation thresholds relative to the 2004 guideline
jurisdiction: US — confidence: unconfirmed — source: pointer only, PubMed PMID (PubMed identifier)=35927519 (efetch) — https://pubmed.ncbi.nlm.nih.gov/35927519/.Why this is not verified despite strong corroboration: the only PubMed-facing connectors in this repo (literature, literature-detail) are Stage 0 scans returning a…the full checkScanResult, which by design carries no confidence tag and has no to_claim_line() — a scan record is a pointer, never evidence (see connectors/result.py). Recorded so a human can convert it: the AAP technical report "Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation" (Pediatrics, 2022) concludes verbatim, "Accumulated evidence justified narrowly raising phototherapy treatment thresholds in the updated clinical practice guideline," and its objective is "To update the evidence base necessary to develop the 2022 American Academy of Pediatrics clinical practice guideline ... Topics addressed in the previous clinical practice guideline (2004) ... were updated." Note the word "narrowly" — the direction the Generator flagged (raised thresholds shrink the treated population, cutting against TAM) is supported, the magnitude is not. Settling this needs the guideline itself read by a human, not a scan pointer.
Moat lever — the defensible assets are the dosimetry record (irradiance x time, per episode, tied to the billing record) and the DME distribution relationship, not the LED array, which is a commodity
jurisdiction: US — confidence: unconfirmed — source: no primary source available. adoption returned unverifiable: "asserts what clinicians, payers, or patients would do ... needs primary research (interviews, survey, published preference study) ... Do NOT substitute a model's own estimate of stakeholder…the full check behaviour." No Verifier judgement is offered in its place. Both of its two supporting legs are also unresolved: the billing-record linkage depends on the E0202 descriptor claim (unconfirmed, missing cache), and no IP (intellectual property) claim exists in this file to check with patent (and PATENTSVIEW_API_KEY is unset, so a patent lookup would return unconfirmed regardless). Re-check 2026-09-29 (second pass): the billing-record leg's dependency now resolves to the descriptor text only — hcpcs E0202 --expect "Phototherapy (bilirubin) light with photometer" --jurisdiction US → verified, local cache of CMS HCPCS Level II file, code=E0202: "HCPCS E0202: Phototherapy (bilirubin) light with photometer" (claim 4verified verified as descriptor wording, not as a payment rule). adoption is still unverifiable; tag unchanged.
Assumption, not a fact: the binding constraint on US home phototherapy adoption is the service model — same-day delivery, in-home setup, parent training, and payer prior authorization — rather than device performance. If that is right, a better device wins little and the real product is a logistics operation. There is no connector for this and no primary research behind it; it is stated here so it stays visible instead of being smuggled in as a market insight
jurisdiction: US — confidence: unconfirmed — source: no primary source available. adoption returned unverifiable with the same detail as above. The connector's suggested rescope to a checkable proxy (coverage for the comparator, procedures for volume) is not available here: both proxies returned…the full check missing-cache unconfirmed, and procedures is Medicare-only against a population with no Medicare exposure. This assumption drives the Moat (2) and Capital-intensity (3) rationales and cannot be checked by any means in this repo. Re-check 2026-09-29: the procedures proxy now runs: procedures E0202 --jurisdiction US → refuted: "No national row for E0202 in the cached supplier-billed release (medicare_dme_volumes.csv), which is the right release for a code of this shape ... Either the code is wrong or it had no Medicare FFS (fee-for-service) supplier volume that year; CMS also omits rows under 11 beneficiaries ... Neither is the same as no market." Read as the connector says — a Medicare FFS absence, uninformative for a newborn population — not as evidence about home phototherapy volume. Tag unchanged. Re-check 2026-09-29 (second pass): the coverage proxy now runs: coverage E0202 --jurisdiction US → refuted, local cache of CMS Medicare Coverage Database (no policy names this code), code=E0202: "No NCD or LCD in the cached coverage file names E0202 ... This is a real reimbursement risk signal, but it is NOT the same as a denial" — read with two limits: the cached file is the MCD Billing & Coding Articles export only (current_article.zip, 1,970 rows), so LCDs and NCDs proper were not searched despite the detail's wording; and coverage tests whether a policy names the code, never whether it is covered. Medicare-only and uninformative about service-model constraints on a newborn population; tag unchanged.
Mechanism and clinical risk — phototherapy efficacy itself is long established; the device-specific risk is under-dosing at home, since delivered irradiance falls with distance and with reduced body-surface coverage, and a home unit has no bedside nurse checking either
jurisdiction: US — confidence: unconfirmed — source: no connector resolves an engineering/clinical-risk assertion of this shape; PubMed is reachable only through Stage 0 scans that cannot carry a confidence tag (see the AAP claim above). One adjacent pointer, tag-less by construction: `recalls --product-code LBI…the full check --since 5y --jurisdiction US returned status none` — "No device recalls for product_code:'LBI' in 2021-08-24 to 2026-08-23." That is a scan, not evidence, and an absence of recalls in a five-year window is not evidence of an absence of the under-dosing failure mode. The dosimetry-accuracy specification remains bench evidence nobody has produced.
Competitive intensity — the LBI class contains established incumbents (Natus, GE) plus at least one recent wearable entrant, and the home segment specifically is served by DME suppliers renting fiberoptic blankets
jurisdiction: US — confidence: unconfirmed — note: compound claim, split it — the first half verified, the second half is unverifiable — source: the incumbent and entrant legs ARE confirmed by claim-typed lookups: openFDA device/510k k_number=K103589 (neoBLUE blanket LED Phototherapy System / Natus Medical…the full check Incorporated), k_number=K120168 (Lullaby LED Phototherapy System / Wipro GE Healthcare Private, Ltd.), k_number=K251308 (SnugLit, wearable, decided 2026-01-15) and k_number=K243372 (BiliWrap, decided 2025-05-29) — i.e. two recent wrap/wearable entrants, not one. The distribution leg — that DME suppliers renting fiberoptic blankets serve the home segment — returned unverifiable from market and is the reason the line as a whole cannot be tagged verified. Recommend the Generator/Scorer split this into a device-landscape claim (verifiable now) and a channel claim (human-attached source required).
Capital intensity and time-to-revenue — a 510(k) against an existing LBI predicate with bench photometric testing and no clinical study is plausibly a low-single-digit-million, 12-24 month path to first revenue
jurisdiction: US — confidence: unconfirmed — source: no primary source available. market returned unverifiable. No connector in this repo returns submission cost, review time, or whether clinical data was required for a given clearance; the 510(k) summaries for the LBI cohort would have to be read individually by…the full check a human to benchmark it, and the go-to-market leg (rental fleet, logistics, days-to-payment) has no public source at all.
A material share of US newborns of 35+ weeks who receive phototherapy are currently treated as inpatients or readmitted for it, rather than treated at home
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — adoption connector returned unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews,…the full check survey, published preference study)."
Discharging birth-hospital clinicians and general pediatricians are willing to substitute home phototherapy for inpatient treatment in the eligible band without an added home bilirubin measurement
jurisdiction: US — confidence: unconfirmed — source: no primary source available. Checked 2026-08-25 (deck-surfaced assumption, desirability deck 2026-08-24). adoption returned unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it…the full check needs primary research (interviews, survey, published preference study) ... Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim." No Verifier judgement is offered in its place, and this line is where that restraint costs the most — it is the assumption the whole home-vs-readmission substitution rests on. Two operational notes. (1) The adoption subcommand takes no --jurisdiction flag (unrecognized arguments: --jurisdiction US), so the in-code jurisdiction guard cannot fire on a claim of this shape at all; the jurisdiction: US tag on this line is therefore carried in prose only and has to be enforced by whoever reads it. (2) The connector's suggested rescopes are both unavailable here: coverage and procedures return missing-cache unconfirmed, and procedures is Medicare-only against a population with no Medicare exposure. Adjacent evidence exists and deliberately does not resolve this — see the home-phototherapy meta-analysis note below; it names bilirubin measurement as a key barrier, but it is a Stage 0 scan pointer, its evidence base is not US-established, and non-US clinician behaviour does not evidence US clinician behaviour. Re-check 2026-09-29: the procedures proxy now runs: procedures E0202 --jurisdiction US → refuted: "No national row for E0202 in the cached supplier-billed release (medicare_dme_volumes.csv), which is the right release for a code of this shape ... Either the code is wrong or it had no Medicare FFS supplier volume that year; CMS also omits rows under 11 beneficiaries ... Neither is the same as no market." Uninformative for a newborn population, as noted above; tag unchanged. Re-check 2026-09-29 (second pass): the coverage proxy now runs: coverage E0202 --jurisdiction US → refuted, local cache of CMS Medicare Coverage Database (no policy names this code), code=E0202: "No NCD or LCD in the cached coverage file names E0202 ... This is a real reimbursement risk signal, but it is NOT the same as a denial" — read with two limits: the cached file is the MCD Billing & Coding Articles export only (current_article.zip, 1,970 rows), so LCDs and NCDs proper were not searched despite the detail's wording; and coverage tests whether a policy names the code, never whether it is covered. Tag unchanged.
The 2022 AAP hyperbilirubinemia guideline addresses home phototherapy and states conditions under which it is acceptable
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — literature-detail 35927519 returned found (Stage 0 scan, no confidence tag assignable). The 2022 AAP Technical Report "Diagnosis and Management of Hyperbilirubinemia in the Newborn Infant 35 or More…the full check Weeks of Gestation" exists and is confirmed to address phototherapy management; the abstract states "Accumulated evidence justified narrowly raising phototherapy treatment thresholds." Whether it specifically addresses home phototherapy conditions requires reading the full guideline text, which is outside this repo's connectors.
Out-of-pocket exposure to the family for a home phototherapy episode is low enough that families do not decline it
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-24) — adoption connector returned unverifiable; this is a payer/cost claim requiring primary research or payer policy documents.
The paying customer for the device is the DME supplier who rents it to the family and bills the payer, not the hospital, the pediatric practice, or the family directly
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — adoption connector returned unverifiable; this is a business-model assumption requiring primary research or market analysis.
Medicaid programs in the largest US birth states publish a coverage policy for home phototherapy for newborns
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — no connector reaches state Medicaid policy; this repo's connectors query national CMS only. Requires human attachment of state Medicaid policy documents (e.g., CA Medi-Cal, TX, NY, FL).
The E0202 rental allowable leaves a DME supplier margin after same-day delivery, in-home setup, parent training and retrieval costs for a 2-4 day episode
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — payment E0202 cache missing (data/hcpcs_payment_rates.csv); no allowable retrieved. Requires human attachment of CMS DMEPOS fee schedule data plus DME operator unit economics (fleet cost, delivery cost,…the full check utilization) from a licensed source or direct operator interview. Re-check 2026-09-29: the Medicare allowable is now retrievable — payment E0202 --jurisdiction US → verified, local cache of CMS DMEPOS fee schedule, code=E0202, modifier=RR, schedule=DMEPOS, release=July 2026: "E0202 — RR (rental), category CR — capped rental items: non-rural $75.86 (AZ) to $89.25 (AL) across 49 contiguous states/DC. ... A fee schedule amount is Medicare's allowed amount, not the payment ... Capped rental (CR): rented monthly, and title passes to the beneficiary after 13 continuous rental months (42 CFR 414.229)." — i.e. a monthly capped-rental Medicare allowed amount, not a per-episode payment by the payers this population actually has (Medicaid, commercial). Supplier unit economics remain unsourced; tag unchanged.
The manufacturer of the cleared wearable predicate (SnugLit, K251308) holds or is building the DME distribution relationships this candidate would need
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-24) — adoption connector returned unverifiable; requires primary research (interviews, licensing data, competitive intelligence) into SnugLit/Thera B Medical Products' current or planned DME distribution channels.
A wrap-form LED array can hold the guideline-specified spectral irradiance over the specified body-surface fraction, on battery, for a full prescribed home episode
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — no connector exists for bench engineering specifications. Requires engineering specification document or bench test data with photometric accuracy validation against 21 CFR 880.5700 special controls and IEC…the full check 60601-2-50.
An onboard radiometer can measure irradiance delivered at the skin, in a garment that moves against a neonate, within a tolerance a reviewer or a payer would accept as a dose record
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — no connector exists for bench sensor-validation data. This is the candidate's core differentiator and requires engineering bench validation data against IEC 60601-2-50 radiometer accuracy requirements, plus…the full check regulatory (FDA) and payer (DME-MAC) acceptability guidance for dose-record accuracy tolerances.
No live, enforceable US patent blocks a wearable LED phototherapy garment with integrated dosimetry, and the FTO (freedom to operate) position has been searched
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — patent connector returned unconfirmed (PATENTSVIEW_API_KEY not set). This is the only claim in the file touching the rubric's sole automatic-kill factor (FTO/IP, Factor 7). No patent search has been…the full check attempted. Requires API key and a focused search on wearable phototherapy devices, onboard radiometric dosimetry, and garment form-factor enclosures, cross-referenced against assignees named elsewhere (Natus, GE, Thera B Medical Products) and the BiliBlanket fiberoptic lineage.
The device can be reprocessed between rental patients to a standard acceptable for neonatal skin contact, or its bill of materials supports single-patient use
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — no connector exists for regulatory or material specifications. A rental business model depends on this; requires either (a) cleaning/reprocessing specification document and biocompatibility validation (ISO (International Organization for Standardization)…the full check 10993 for neonatal skin contact), or (b) cost analysis of single-patient disposable BOM (bill of materials) against rental economics.
FDA would accept an LBI-cleared device as predicate for this narrower in-band indication with a dosimetry feature on bench photometric data alone, without clinical data
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-24) — no connector can answer FDA substantial-equivalence judgments. The Factor 1 score of 4 and the Capital-intensity factor both rest on this assumption being true. The closest analog (SnugLit K251308) has a…the full checkbroader cleared indication (no gestational-age floor, no bilirubin-band ceiling) than this candidate proposes; whether narrowing an indication plus adding a dosimetry feature (not claimed by the predicate) survives substantial-equivalence scrutiny is an FDA judgment, not a database fact. Requires FDA feedback letter or pre-submission meeting minutes, or a legal FTO opinion.
The bilirubin measurement extension carried as the second device_class route lands on in-vitro bilirubin test-system generic types, of which two are identified: 21 CFR 862.1110 / product code CIG / Class II ("Bilirubin (total or direct) test system") and 21 CFR 862.1113 / product code MQM / Class I ("Bilirubin (total and unbound) in the neonate test system")
jurisdiction: US — confidence: verified — source: openFDA device/classification product_code=CIG ("Device class 2: Diazo Colorimetry, Bilirubin (regulation 862.1110, review panel CH)") and product_code=MQM ("Device class 1: Bilirubin (Total And Unbound) In The Neonate Test System (regulation 862.1113, review panel…the full check CH)"), plus eCFR versioner title-21, issue 2026-08-19, sections 862.1110 and 862.1113 read verbatim. 862.1110: "A bilirubin (total or direct) test system is a device intended to measure the levels of bilirubin (total or direct) in plasma or serum ... (b) Classification. Class II." 862.1113: "A bilirubin (total and unbound) in the neonate test system is a device intended to measure the levels of bilirubin (total and unbound) in the blood (serum) of newborn infants to aid in indicating the risk of bilirubin encephalopathy (kernicterus). (b) Classification. Class I." Three things this establishes about the carried route, none of which is scored here. (1) The neonate-specific generic type is Class I, not the Class II the device_class frontmatter asserts for this route; the Class II reading fits only the general 862.1110 test system. Which one applies depends on the measurement claim actually made — a Generator decision, not a connector output. Frontmatter flagged, not edited. (2) Both sections scope themselves to plasma/serum or blood, i.e. an in-vitro draw; neither text reaches a non-invasive skin measurement (see next claim). (3) The review panel on both is CH (clinical chemistry), not the HO panel that carries the LBI launch route — which is the concrete, record-backed form of the file's own statement that a measurement claim is "a separate review."
The transcutaneous (non-invasive) bilirubinometer route the frontmatter describes has an identifiable FDA generic type, product code and regulation number
jurisdiction: US — confidence: unconfirmed — source: no classification record located. classification --device-name "<name>" --jurisdiction US returned "No classification record found" for each of: "transcutaneous bilirubinometer", "bilirubinometer", "transcutaneous bilirubin", "bilirubin, transcutaneous", "meter,…the full check bilirubin, transcutaneous", "photometer, bilirubin", "bilirubin, spectrophotometric", "analyzer, bilirubin", "noninvasive bilirubin", "bilirubin, neonatal", "bilirubin test system", "jaundice". The only two names that matched are the in-vitro types in the claim above, and 21 CFR 862.1113's own text rules out a transcutaneous reading of that section by scoping itself to "blood (serum)". This is a name-matching miss, not a finding that no such route exists — the openFDA classification endpoint is queried by exact generic-type name, and a bounded sweep that fails to guess the right string proves nothing about the device landscape. (The same pass saw this failure mode directly: 510k "SnugLit Wearable Phototherapy System" --applicant "Thera B Medical Products" returns refuted for a device that demonstrably exists — see the pass note.) So the frontmatter's "regulation number NOT identified by the Generator" still stands after a Verifier attempt, and the second device_class route remains a named intention rather than a checked pathway. Closing it needs the generic-type name or product code off an actual cleared transcutaneous bilirubinometer's classification record — a human read, or a Generator-supplied product code a later pass can check directly in one call.
Ordering clinicians will use a per-episode irradiance-and-adherence record from a home phototherapy device to make a management decision they cannot make today, rather than treating it as documentation they ignore
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (desirability deck, 2026-08-25) — adoption connector returned unverifiable; this is a clinician-behavior claim requiring primary research (interviews, chart-review analysis, published preference study).
A DME supplier stocking a home phototherapy rental fleet will choose a dosimetry-equipped wearable over the already-cleared SnugLit wearable (K251308), whose cleared indication is broader and carries no dose record
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (viability deck, 2026-08-25) — adoption connector returned unverifiable; this is a competitive-preference claim requiring primary research (interviews with DME operators, fleet purchasing decisions, pricing analysis).
A single wrap size holds emitter-to-skin and sensor-to-skin geometry across the 1.5-5.5 kg / 40.5-57.5 cm neonatal size range the cleared analog's indication spans, so that a logged dose means the same thing at both ends of that range
jurisdiction: US — confidence: unconfirmed — source: deck-surfaced assumption (feasibility deck, 2026-08-25) — no connector exists for bench ergonomic/optical specifications. Requires engineering design document and validation data (optical bench testing across size range) showing emitter-to-skin and sensor-to-skin…the full check distances remain within photometric accuracy tolerances across the full indicated neonatal size range.
US births totaled 3,628,934 in 2024, up 1% from 3,596,017 in 2023
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §1 (2026-08-27) — primary source: PMID 40996517 (CDC/NCHS Data Brief No. 535, 'Births in the United States, 2024') — literature-detail 40996517 returned found (Stage 0 scan); PubMed…the full check abstract confirmed: "The number of births in the United States increased 1% from 2023 to 2024, to 3,628,934 births." Stage 0 scan carries no confidence tag by construction; cannot be upgraded to verified.
Among 148,162 infants at least 35 weeks gestation born 2012-2017 at 11 Kaiser Permanente Northern California facilities who did not receive phototherapy during the birth hospitalization, 1.8% (2,623 infants) exceeded the AAP phototherapy threshold after discharge
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §1 (2026-08-27) — primary source: PMID 33903163 — literature-detail 33903163 returned found (Stage 0 scan); abstract confirmed the Kaiser Permanente Northern California cohort…the full check (2012-2017, n=148,162, 35+ weeks) and result: "A total of 2623 infants (1.8%) exceeded the phototherapy threshold postdischarge." Stage 0 scan carries no confidence tag; cannot be upgraded.
In a US retrospective review of 359 newborns across 9 pediatric clinics with discharge total serum bilirubin 0.1-3 mg/dL below the inpatient phototherapy threshold, home biliblanket use (44% of newborns) was associated with a lower readmission rate (4%) than no biliblanket use (13%), OR 0.16 (95% CI 0.06-0.44)
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: PMID 36476052 — literature-detail 36476052 returned found (Stage 0 scan); abstract confirmed: "Home biliblankets were used for 44% of newborns" and…the full check "Four percent of newborns treated with a biliblanket were readmitted compared with 13% of those not treated with a biliblanket (P = .002). ... Newborns treated with a biliblanket (odds ratio [OR] = 0.16; 95% confidence interval [CI] = 0.06-0.44)." Stage 0 scan carries no confidence tag.
A 2024 systematic review and meta-analysis of 9 studies (998 patients, 4 RCTs and 5 cohort studies) found hospital readmission was higher with home phototherapy than inpatient phototherapy (RR=4.61, 95% CI 1.43-14.86, P=0.01), grading the overall evidence quality as very low
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: PMID 38433210 — literature-detail 38433210 returned found (Stage 0 scan); abstract confirmed: "Nine studies (998 patients) were included (four RCTs,…the full check five cohort studies)" and "Hospital readmission was higher with HPT (RR = 4.61; 95% CI: 1.43-14.86, P = 0.01)" and "The evidence quality was very low." Stage 0 scan carries no confidence tag.
A 2026 mixed-methods systematic review and meta-analysis of 31 studies found a pooled hospital (re)admission rate of 3.5% (95% CI 2.2-5.3%) following home phototherapy initiation, rated evidence quality low for all outcomes, and found no studies evaluating cost-effectiveness
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: PMID 40715357 — literature-detail 40715357 returned found (Stage 0 scan); abstract confirmed: "Thirty-one studies were included" and "Hospital…the full check (re)admission following home phototherapy was 3.5% (95% CI, 2.2-5.3%)" and "No studies evaluated cost-effectiveness" and "Quality of evidence was rated low for all outcomes." Stage 0 scan carries no confidence tag.
A first-in-human pilot study of a wearable phototherapy device in 12 near-term/term neonates found phototherapy completed within 48 hours in 83% (10/12), with 2 of 12 switched to conventional intensive phototherapy because bilirubin kept rising despite wearable treatment
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: PMID 40488806 — literature-detail 40488806 returned found (Stage 0 scan); abstract confirmed: "Twelve neonates were included" and "In ten neonates…the full check (83%), phototherapy was successfully completed within 48 h" and "Two neonates were switched to conventional intensive phototherapy due to the ongoing rise of bilirubin levels despite wearable phototherapy treatment." Jurisdiction note: This study is from Erasmus MC Sophia Children's Hospital in Rotterdam, Netherlands (Dutch setting); not US-conducted. Stage 0 scan carries no confidence tag.
A qualitative implementation study of 21 healthcare professionals and 10 parents identified lack of reimbursement options and difficulty reaching all relevant healthcare professionals for education as the main barriers to home phototherapy implementation
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: PMID 40043639 — literature-detail 40043639 returned found (Stage 0 scan); abstract confirmed: "Five focus group interviews with 21 healthcare…the full check professionals and 10 semi-structured interviews with parents" and "Barriers concerned the lack of reimbursement options and the challenge to reach all the different healthcare professionals for education." Jurisdiction note: Study reports geographic setting as unclear from abstract, but the journal is UK-based (Midwifery); needs full-text review to confirm US setting or other. Stage 0 scan carries no confidence tag.
A one-time survey of Canadian paediatricians found 58 of 497 respondents (12%) worked at a centre offering home phototherapy, and 15 physicians (3%) reported 21 adverse-event cases associated with home phototherapy in the preceding 12 months, most resulting in hospital admission or readmission for inpatient phototherapy, with no serious AEs reported
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: PMID 40756546 — literature-detail 40756546 returned found (Stage 0 scan); abstract confirmed: "58 (12%) reported working at a centre that provides HP"…the full check and "15 (3%) physicians with 21 cases of AEs associated with HP in the preceding 12 months. Most AEs resulted in admissions or readmissions to the hospital for inpatient phototherapy. No serious AEs or long-term consequences were reported." Jurisdiction mismatch: This is a Canadian survey, not US. The jurisdiction: US tag on this claim is inapplicable; it should be jurisdiction: CA. Stage 0 scan carries no confidence tag.
HCPCS E0202 carries a Louisiana Medicaid DMEPOS fee-schedule payment of $33.71 (type-of-service modifier 09, rate effective 2021-09-01) under the schedule effective for dates of service 2024-10-01 and forward, alongside a second, lower entry of $30.90 (modifier 07, rate effective 2012-07-01)
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §6 (2026-08-27) — primary source: Louisiana Medicaid DMEPOS Fee Schedule, Report RF (radiofrequency)-0-76D, Louisiana Department of Health, https://www.lamedicaid.com/provweb1/fee_schedules/dmefee.pdf — no…the full check connector reaches state Medicaid fee schedules; this repo's connectors query national CMS only. The Louisiana Medicaid DMEPOS fee schedule is a human-attached source (licensed state document). Payment rates vary significantly by state, and this is one state's rate, not a representative or negotiated national rate. The claim's specificity (exact rates and effective dates) requires human verification against the cited source.
In a 2026 survey of US birthing hospitals in the BORN network (67 of 123 contacted, 55% response rate), only 24% of respondents reported obtaining a transcutaneous bilirubin measurement at least 24 hours after phototherapy discontinuation as the 2022 AAP guideline recommends
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §6 (2026-08-27) — primary source: PMID 41500508 — literature-detail 41500508 returned found (Stage 0 scan); abstract confirmed: "One hundred twenty-three birthing hospitals were…the full check contacted, with 67 participants (55% response rate)" and "only 24% of respondents utilized a transcutaneous bilirubin measurement at least 24 hours after phototherapy discontinuation" per the 2022 AAP guideline. The gap (76% non-compliance) is directly relevant to the candidate's design assumption that clinicians will use a home phototherapy dosimetry record. Stage 0 scan carries no confidence tag.
The Natus neoBLUE blanket LED Phototherapy System (K103589) was the subject of two FDA recalls for discoloration/degradation of the fiberoptic bundle at the connection of the pad and box
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: openFDA device/recall product_res_number=Z-0770-2017, Z-0769-2017 — recalls --product-code LBI returned status none (Stage 0 scan, "No device recalls…the full check for product_code:'LBI' in 2021-08-30 to 2026-08-29"). The specific recall numbers (Z-0770-2017, Z-0769-2017) cited in the claim fall outside the 5-year window searched (2017 dates vs. 2021-2026 window). A full openFDA recall search from 2017 onward would be needed to verify. Stage 0 scan carries no confidence tag.
FDA recorded 10 distinct 510(k) clearances under product code LBI in the 2016-08-29 to 2026-08-27 scan window, including two wrap/wearable-garment entrants cleared in 2025-2026 (BiliWrap K243372 and SnugLit K251308)
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: openFDA device/510k product_code=LBI — clearances --product-code LBI --since 10y returned found (Stage 0 scan, "10 510(k) clearance(s) for…the full check product_code:'LBI' in 2016-08-31 to 2026-08-29"). All 10 records confirmed: K251308 (SnugLit, 2026-01-15), K243372 (BiliWrap, 2025-05-29), plus K210289, K200031, K190899, K182178, K172656, K170585, K163526, K160745. The claim's statement "cleared in 2025-2026" is accurate for both wearable entrants (K251308 at 2026-01-15, K243372 at 2025-05-29). Stage 0 scan carries no confidence tag.
A US randomized trial (NCT03599258 (a ClinicalTrials.gov registration number), sponsor HonorHealth Research Institute, enrollment 72 actual) compared Neolight Skylife phototherapy to standardized phototherapy for newborn hyperbilirubinemia, tracking skin-irritation and temperature-control safety endpoints; it completed 2021-05-27 with no results posted on ClinicalTrials.gov
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §5 (2026-08-27) — primary source: ClinicalTrials.gov NCT03599258 — no connector available in this repo for ClinicalTrials.gov queries (trial-detail was attempted but did not execute…the full check successfully). The claim asserts a specific trial outcome (completion date 2021-05-27, enrollment 72, no results posted). This requires human verification against the live ClinicalTrials.gov registry entry at https://clinicaltrials.gov/study/NCT03599258.
Parents would prefer home phototherapy over inpatient admission or readmission for treating neonatal hyperbilirubinemia — unanswerable as stated; the revealed-behaviour twin researched instead is the home-phototherapy (re)admission and adverse-event rate recorded as claims 39, 40 and 43 above
jurisdiction: US — confidence: unconfirmed — source: research lane, from dossier neonatal-hyperbilirubinemia-home-phototherapy §9 (2026-08-27) — evidence class 3 (stakeholder future); adoption connector returned unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative,…the full check machine-queryable source answers that — it needs primary research (interviews, survey, published preference study)." No source can settle this claim in its stated form. The dossier correctly notes that the revealed-behaviour twin (actual home-phototherapy utilization, readmission rates, adverse events) is more verifiable and is recorded in claims 39, 40, 41 above.
The share of annual US births at 35 or more weeks gestation is high enough that an all-births denominator and a 35-plus-week phototherapy rate can be multiplied without material error
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — no connector reads NCHS natality by gestational age; the answer exists in a free federal source (CDC WONDER natality) but outside this repo's connector set — needs a human attachment — source: business-case…the full check assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
The Louisiana Medicaid E0202 allowable of $33.71 is paid per day of rental rather than per episode, per rental month, or as a purchase
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — no connector reaches state Medicaid fee schedules or their billing unit; the Medicare DMEPOS line for the same code is a monthly capped rental, which is a different payer and does not settle the Louisiana unit…the full check either way — source: business-case assumption (2026-09-03) — payment E0202 --state LA --jurisdiction US → verified (for Medicare only), local cache of CMS DMEPOS fee schedule, code=E0202, modifier=RR, state=LA, schedule=DMEPOS, release=July 2026: "E0202 — RR (rental), category CR — capped rental items: LA non-rural $89.25 ... Capped rental (CR): rented monthly" — does not answer this claim, which is about Louisiana Medicaid
A DME supplier's fully-loaded cost to deliver one home phototherapy episode, including same-day delivery, in-home setup, parent training, retrieval and reprocessing, is below the E0202 allowable for that episode
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — supplier cost is unsourced; the Medicare side of the comparator is a monthly RR allowable (see claim 5verified), not a per-episode one, and not the relevant payer's — source: business-case assumption (2026-09-03) — market…the full check on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
The price a DME supplier would pay per home phototherapy fleet unit is high enough to support a device business at achievable US volumes
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed…the full check report and edits the claim by hand."
A home phototherapy fleet unit turns enough episodes per year to repay its acquisition price within the fleet's useful life
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed…the full check report and edits the claim by hand."
A material share of addressable US home phototherapy episodes would be served on a dosimetry-equipped wearable by year 3
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — adoption on this claim's text → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that —…the full check it needs primary research (interviews, survey, published preference study)." (adoption takes no --jurisdiction flag)
Gross margin on the device at the achievable DME fleet price supports the business
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed…the full check report and edits the claim by hand."
A logged irradiance-and-adherence record earns incremental payment from a payer, as a modifier, a higher-paying code, or satisfaction of a documentation condition
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — no connector answers whether a documentation feature earns payment; the Medicare DMEPOS schedule carries a single RR line for E0202 with no dose-record modifier, and coverage policy (where a documentation condition…the full check would live) is uncached — source: business-case assumption (2026-09-03) — payment E0202 --jurisdiction US → verified (the one Medicare line that exists; says nothing about incremental payment), local cache of CMS DMEPOS fee schedule, code=E0202, modifier=RR, schedule=DMEPOS, release=July 2026: "E0202 — RR (rental), category CR — capped rental items: non-rural $75.86 (AZ) to $89.25 (AL) across 49 contiguous states/DC. ... A fee schedule amount is Medicare's allowed amount, not the payment ... Capped rental (CR): rented monthly, and title passes to the beneficiary after 13 continuous rental months (42 CFR 414.229)."; coverage E0202 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv" (file still absent from data/) Re-check 2026-09-29 (second pass): the coverage leg now runs: coverage E0202 --jurisdiction US → refuted, local cache of CMS Medicare Coverage Database (no policy names this code), code=E0202: "No NCD or LCD in the cached coverage file names E0202 ... This is a real reimbursement risk signal, but it is NOT the same as a denial" — read with two limits: the cached file is the MCD Billing & Coding Articles export only (current_article.zip, 1,970 rows), so LCDs and NCDs proper were not searched despite the detail's wording; and coverage tests whether a policy names the code, never whether it is covered — so no cached Medicare billing article names E0202 at all, let alone attaches a documentation condition a dose record could satisfy. Consistent with, but not a refutation of, this claim (Medicaid/commercial policies are out of reach). Tag unchanged.
The lag from first fleet delivery to first paid E0202 claim, covering payer enrollment, prior authorization and the claims cycle, is short enough to finance
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — adoption on this claim's text → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that —…the full check it needs primary research (interviews, survey, published preference study)." (adoption takes no --jurisdiction flag)
DME channel coverage in the largest US birth states can be built at a cost and calendar the clearance budget can absorb
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed…the full check report and edits the claim by hand."
DMEPOS supplier enrollment and accreditation, plus per-state Medicaid enrollment in the largest US birth states, is affordable within a launch budget
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed…the full check report and edits the claim by hand."
The dosimetry subsystem can be qualified as an OEM module into an already-cleared LBI device without a new full 510(k) for the host device
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — whether a module change requires a new 510(k) is an FDA interpretation of 21 CFR 807.81(a)(3), which the regulation text does not settle; FDA guidance on device modifications is out of connector reach — source:…the full check business-case assumption (2026-09-03) — regulation 807.81 --expect "could significantly affect the safety or effectiveness" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-25, section=807.81 — the text establishes only that a change which "could significantly affect the safety or effectiveness of the device" or a major change in intended use requires a new premarket notification; it does not say whether this module does
A US comparative study large enough to produce a readmission differential attributable to home phototherapy with a dose record is affordable and can be run in a useful calendar
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: business-case assumption (2026-09-03) — market on this claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed…the full check report and edits the claim by hand."
The Medicaid share of US births is large enough that Medicaid rates, not commercial rates, set the effective price of the addressable home phototherapy pool
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — the Medicaid birth-share figure has a free federal source (NCHS natality, source of payment) outside this repo's connectors — human attachment needed — source: business-case assumption (2026-09-03) — market on this…the full check claim's text → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
The onboard dosimetry accuracy question can be settled by bench testing alone — a reference photometer, a neonatal phantom and the garment — without human subjects, regulatory interaction or payer input
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — no connector answers what evidence FDA or a payer would require; 21 CFR 880.5700 carries no special-controls text to anchor a bench-only argument either way — source: unsubstantiated message (investor set,…the full check 2026-09-03) — regulation 880.5700 --expect "special controls" --jurisdiction US → unconfirmed, eCFR versioner title-21, issue 2026-09-25, section=880.5700: "exists but its text does NOT contain the phrase 'special controls' ... (b) Classification. Class II (performance standards)."
Per-episode delivered-dose records generated in routine use constitute usable clinical evidence for this device's own regulatory and payer submissions
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — a regulatory/payer evidence-acceptability judgement; no connector answers it — source: unsubstantiated message (investor set, 2026-09-03) — adoption on this claim's text → unverifiable: "asserts what clinicians,…the full check payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews, survey, published preference study)." (adoption takes no --jurisdiction flag)
Newborns under 35 weeks gestational age, newborns with complicated or hemolytic hyperbilirubinemia, and newborns at or above the escalation-of-care threshold are appropriately excluded from home phototherapy with this device and are treated elsewhere
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — clinical-practice appropriateness; the 2022 AAP guideline is reachable only as a Stage 0 scan pointer (claims 12, 21), which carries no tag — source: unsubstantiated message (user set, 2026-09-03) — adoption on…the full check this claim's text → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source answers that — it needs primary research (interviews, survey, published preference study)." (adoption takes no --jurisdiction flag)
Payer prior authorization for home phototherapy of a newborn can be obtained within the clinical window, measured in hours rather than days, in which the treatment episode must start
jurisdiction: US — confidence: unconfirmed — note: checked 2026-09-29; no connector can resolve this — source: unsubstantiated message (payer set, 2026-09-03) — adoption on this claim's text → unverifiable: "asserts what clinicians, payers, or patients would do. No free, authoritative, machine-queryable source…the full check answers that — it needs primary research (interviews, survey, published preference study)." (adoption takes no --jurisdiction flag)
State Medicaid programs and commercial plans in the largest US birth states pay newborn home phototherapy predominantly under the per-diem home phototherapy service code S9098, whose descriptor bundles equipment rental with nursing services and blood draw, rather than under the equipment code E0202
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it
A payer that prices E0202 as a monthly rental pays one full rental month's allowable for a home phototherapy episode lasting 2-4 days, rather than a prorated or per-day amount
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it
HCPCS E0202 has no row in the CMS Physician Fee Schedule RVU (relative value unit) file, so no practice-expense RVU carries the cost of a device billed under it
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it
A hospital readmission of a newborn for phototherapy is paid to the hospital as a per-case DRG amount by state Medicaid programs and most commercial plans, so the cost avoided by home phototherapy accrues to the payer rather than the hospital outside capitated or value-based contracts
jurisdiction: US — confidence: unverified — source: business-case assumption (2026-09-29) — never checked; recorded so the Verifier can see it
Families of in-band newborns on home phototherapy complete the ordering clinician's scheduled outpatient serum bilirubin draws during the episode on time, without in-home nursing support
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-29) — never checked; recorded so the Verifier can see it
State Medicaid programs and commercial plans that pay E0202 deny, reduce or recode a claim for a phototherapy light supplied without a photometer, so that the photometer is a payment condition and not only descriptor wording
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-29) — never checked; recorded so the Verifier can see it
FDA treats a per-episode delivered-irradiance and adherence record transmitted to the ordering clinician as a feature of a neonatal phototherapy unit under 21 CFR 880.5700, not as a bilirubin measurement or other function requiring a separate classification or submission
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-29) — never checked; recorded so the Verifier can see it
A battery-powered wrap-form LED array delivering the prescribed irradiance keeps its skin-contact surfaces within the temperature limits applicable to neonatal phototherapy equipment for the full duration of a home episode
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-29) — never checked; recorded so the Verifier can see it
Home phototherapy blankets currently rented to families of newborns are billed to state Medicaid programs and commercial plans under HCPCS E0202, so a dosimetry-equipped wearable billed under E0202 substitutes within existing E0202 spend rather than adding a new benefit line
jurisdiction: US — confidence: unverified — source: unsubstantiated message (payer set, 2026-09-29) — never checked; recorded so the Verifier can see it
Words on this page27 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md
21 CFR
Title 21 of the Code of Federal Regulations — the US food-and-drug rulebook; a number after it is one regulation, often the one that classifies a device type
510(k)
premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
BOM
bill of materials — the list of parts in a product and what each costs
Class II
FDA device class II — moderate-risk devices, usually cleared by 510(k)
CMS
Centers for Medicare & Medicaid Services — the US agency that runs Medicare, and so decides what Medicare pays for
DME
durable medical equipment — equipment a patient uses at home, such as a pump or a stimulator, that Medicare pays for under its own rules
DME MAC
durable medical equipment Medicare administrative contractor — one of the four regional contractors that process Medicare's home-equipment claims and write its local coverage rules
DMEPOS
durable medical equipment, prosthetics, orthotics and supplies — the Medicare benefit and fee schedule that home equipment is paid under
E####
a HCPCS code for durable medical equipment — one billing code for a piece of home equipment; the letter E and four digits
FDA
US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
FFS
fee-for-service — the traditional form of Medicare that pays per item or service
FTO
freedom to operate — whether a product can be sold without infringing someone else's live patent
HCPCS
Healthcare Common Procedure Coding System — the US billing codes for equipment, supplies and some services; a code is how a payer recognises what to pay for
IFU
instructions for use — the labelling that says what a device is for and how to use it
IP
intellectual property — patents and the other rights that let a company stop others copying it
ISO
International Organization for Standardization — the body whose numbered standards devices and laboratories are tested against
K######
an FDA 510(k) clearance number — the public record of one cleared device; the letter K and six digits
LCD
local coverage determination — a Medicare contractor's rule, valid in its region, saying when something is covered
MAC
Medicare administrative contractor — a regional contractor that processes Medicare claims and writes local coverage rules
NCD
national coverage determination — a Medicare rule, valid everywhere in the US, saying whether and when something is covered
NCT########
a ClinicalTrials.gov registration number — the public id of one registered clinical trial
PDAC
Pricing, Data Analysis and Coding contractor — the Medicare contractor that decides which billing code a specific product falls under
PMID
PubMed identifier — the public id of one published medical paper
RF
radiofrequency — heating tissue with a radio-frequency electrical current
RVU
relative value unit — the unit Medicare uses to price a clinician's work
S####
a HCPCS temporary national code — a billing code used by some private payers and not by Medicare
TAM
total addressable market — how much money the whole market would be worth if every possible buyer bought